Rousselot launches Nextida collagen peptides

NEXTIDA features a composition of collagen peptides that support health benefits beyond traditional collagen solutions

Rousselot has launched NEXTIDA, a platform of collagen peptide compositions with new targeted health benefits. Built and backed by science, Nextida supports the body’s balance naturally.

Nextida is comprised of collagen peptide compositions which can trigger new modes of actions for specific health benefits. A testing and validation process involving preclinical and clinical studies will be conducted, including the evaluation of the composition’s efficacy and safety.

“After years of cutting-edge research into the collagen molecule, Rousselot is proud to launch Nextida, offering new health benefits beyond those traditionally attributed to collagen peptides. Nextida’s strength and innovation is to act where it matters,” said Jeroen Colpaert, executive vice-president of Rousselot.

Nextida.GC will be the first commercialised specific collagen peptides from the Nextida platform. Nextida.GC aims to reduce the post meal sugar spike in a natural way in healthy individuals. Results from scientific studies on the impact of Nextida.GC on glucose metabolism will be unveiled at the annual SupplySide West event in Las Vegas, 28-31 Oct 2024.

“This new product marks the beginning of a long series of innovations, building on Rousselot’s unique scientific and production excellence,” Colpaert said. “We are incredibly excited to open new market opportunities with Nextida and to further empower customers who are looking for natural health and wellness products.”